CDC Laboratory Science and Research Capabilities

The CDC's laboratory science and research infrastructure forms the diagnostic and analytical backbone of the United States public health system. This page covers the scope of CDC laboratory operations, the mechanisms by which those laboratories detect and characterize pathogens, the scenarios in which laboratory capabilities are deployed, and the criteria that determine which laboratory level handles a given threat. Understanding these capabilities is essential for grasping how the agency translates biological specimens into actionable public health guidance.

Definition and scope

CDC laboratory science encompasses the full spectrum of activities from pathogen detection and genomic characterization to applied research on disease mechanisms, environmental contaminants, and occupational exposures. The agency operates more than 25 specialized laboratories distributed across its Atlanta, Georgia headquarters and satellite facilities, including the Roybal Campus, the Chamblee Campus, and operations embedded within the CDC's centers, institutes, and offices.

The scope extends beyond infectious disease. CDC laboratories conduct research in four broad domains:

1. Infectious disease diagnostics — Identification of bacterial, viral, fungal, and parasitic pathogens using culture, serology, polymerase chain reaction (PCR), and next-generation sequencing.
2. Environmental and occupational health testing — Chemical exposure biomonitoring, radiation measurement, and workplace hazard quantification conducted in partnership with the National Institute for Occupational Safety and Health (NIOSH).
3. Chronic disease biomarkers — Laboratory analysis supporting surveillance of conditions such as diabetes, cardiovascular disease, and cancer risk factors.
4. Preparedness and countermeasure research — Development and validation of diagnostic assays and reference materials for use during declared public health emergencies.

The CDC's Division of Laboratory Systems (DLS), housed within the Center for Surveillance, Epidemiology, and Laboratory Services (CSELS), sets quality standards for the broader U.S. clinical laboratory network under the Clinical Laboratory Improvement Amendments (CLIA), codified at 42 CFR Part 493 (Centers for Medicare & Medicaid Services, CLIA regulations).

How it works

CDC laboratories function as reference laboratories — the highest tier in a three-tier hierarchy that also includes state public health laboratories and local or hospital-based clinical laboratories. This hierarchy determines how specimens move through the system and at what level a definitive identification is made.

Tier comparison: Clinical vs. State vs. CDC reference

• Clinical/local laboratories perform rapid, high-volume screening using commercially available assays. They confirm common pathogens but lack the biosafety infrastructure or validated methods to work with Select Agents or novel organisms.
• State public health laboratories (51 jurisdictions, including the District of Columbia, each operating at least one facility) handle confirmatory testing and serve as the first escalation point when a clinical laboratory cannot resolve a result.
• CDC reference laboratories receive specimens that state labs cannot identify, that represent a potential bioterrorism agent, or that require genomic surveillance work to characterize strain variation across a population.

The Laboratory Response Network (LRN), established in 1999 through a partnership between CDC, the Association of Public Health Laboratories (APHL), and the Federal Bureau of Investigation (FBI), formalizes this escalation architecture (CDC Laboratory Response Network). The LRN connects more than 100 domestic laboratories — categorized as Sentinel, Reference, or National — to enable coordinated response to biological, chemical, and radiological threats.

Genomic sequencing has become central to CDC laboratory operations. The agency's Advanced Molecular Detection (AMD) program, launched formally in 2014 with an initial congressional appropriation of $30 million (CDC AMD program overview), integrates whole-genome sequencing, bioinformatics, and epidemiological data to track pathogen evolution and outbreak clustering in near real time. AMD output feeds directly into the CDC disease surveillance systems that generate national epidemiological intelligence.

Biosafety level (BSL) infrastructure governs which pathogens can be handled and where. BSL-4, the highest classification under CDC and NIH guidelines, permits work with agents such as Ebola virus and Marburg virus for which no approved vaccine or therapy exists (CDC/NIH Biosafety in Microbiological and Biomedical Laboratories, 6th ed.). The CDC operates BSL-4 laboratory space at its Atlanta campus — one of a small number of such facilities in the United States.

Common scenarios

Laboratory science capabilities are activated across a defined set of recurrent operational scenarios:

Outbreak investigation support — When field epidemiologists identify a cluster of illness without a confirmed etiology, CDC laboratories receive specimens for pathogen identification. This workflow is detailed in the CDC outbreak investigation process. During the 2014–2016 West Africa Ebola outbreak response, CDC deployed mobile laboratory units capable of processing specimens under field conditions, reducing diagnostic turnaround from days to under 4 hours.

Surveillance and genomic monitoring — The National Wastewater Surveillance System (NWSS), operationalized at scale beginning in 2020, relies on CDC laboratory protocols to detect and quantify pathogen nucleic acids in municipal wastewater samples from more than 1,400 sites (CDC NWSS), enabling population-level trend detection independent of clinical testing rates.

Select Agent and bioterrorism response — Under 42 CFR Part 73, the CDC regulates possession, use, and transfer of biological Select Agents and Toxins (eCFR 42 CFR Part 73). When a suspicious specimen is flagged — whether from a law enforcement referral or an anomalous clinical presentation — LRN National laboratories at CDC perform definitive identification using validated reference methods.

Vaccine strain and antimicrobial resistance tracking — CDC's National Center for Immunization and Respiratory Diseases (NCIRD) and the National Antimicrobial Resistance Monitoring System (NARMS), a joint program with the FDA and USDA, use laboratory characterization to detect shifts in pathogen populations that would affect vaccine formulation or treatment guidelines (NARMS program).

Decision boundaries

Not every specimen or research question reaches CDC laboratories. Several explicit criteria govern escalation and resource allocation:

1. Diagnostic resolution failure — A specimen advances to CDC only when validated methods at lower-tier laboratories have failed to produce an actionable result, or when the suspected agent requires BSL-3 or BSL-4 containment.
2. Public health significance threshold — CDC laboratory resources prioritize pathogens with outbreak potential, novel genetic characteristics, or designation as a Category A, B, or C bioterrorism agent by the National Institute of Allergy and Infectious Diseases (NIAID) classification framework (NIAID biodefense categories).
3. Regulatory jurisdiction — Laboratory testing related to food safety contaminants may fall under FDA or USDA jurisdiction rather than CDC, depending on the implicated commodity. The interagency Integrated Food Safety System defines these handoff points explicitly.
4. Research vs. diagnostic function — CDC laboratories distinguish between public health diagnostic activities — which carry no patient fee and are performed under public health authority — and applied research programs, which are funded through appropriations, cooperative agreements, or interagency transfers and follow separate protocols under the Federal Technology Transfer Act.
5. International specimen receipt — Cross-border specimen transfer requires coordination with the Division of Global Migration and Quarantine and compliance with both U.S. import permit requirements and the Nagoya Protocol's access and benefit-sharing provisions for genetic resources, a distinction relevant to CDC's global health operations.

The CDC's broader mandate and authority structure provides the statutory framework within which all laboratory operations are authorized, funded, and accountable to congressional oversight.